methyl 2-phenylethanimidothioate iodide | 30859-65-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-phenylethanimidothioate iodide
• 英文别名: 2-phenyl-thioacetimidic acid methyl ester; hydriodide；2-Phenyl-thioacetimidsaeure-methylester; Hydrojodid；Methyl 2-phenylethanimidothioate;hydroiodide
• CAS: 30859-65-5
• 化学式: C₉H₁₁NS*HI
• 分子量: 293.171
• InChiKey: QJSCZKCUIAPWTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.19
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  49.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 2-phenylethanimidothioate iodide 在 sodium carbonate 、 溶剂黄146 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 (4S,5R,6R)-5-Acetylamino-6-(5-benzyl-1-propyl-1H-[1,2,4]triazol-3-yl)-4-tert-butoxycarbonylamino-5,6-dihydro-4H-pyran-2-carboxylic acid benzhydryl ester
  参考文献：
  名称：

  Novel inhibitors of influenza sialidases related to zanamivir. Heterocyclic replacements of the glycerol sidechain

  摘要：

  A series of substituted 4-amino-4H-pyran-2-carboxylic acid 6-triazoles and oxadiazoles are described. The compounds are inhibitors of influenza virus sialidases which: in general, show a similar pattern of activity and selectivity to recently reported 4H-pyran-2-carboxylic acid 6-carboxamides. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00399-5
• 作为产物：
  描述：

  碘甲烷 、 2-苯基硫代乙酰胺 以 丙酮 为溶剂， 反应 15.0h， 以97%的产率得到methyl 2-phenylethanimidothioate iodide
  参考文献：
  名称：

  Combretastatin A4-β-Galactosyl Conjugates for Ovarian Cancer Prodrug Monotherapy

  摘要：

  Chemotherapy for ovarian cancer often causes severe side effects. As candidates for combretastatin A4 (CA4) prodrug for ovarian cancer prodrug monotherapy (PMT), we designed and synthesized two beta-galactose-conjugated CA4s (CA4-beta Gals), CA4-beta Gal-1 and CA4-beta Gal-2. CA4 was liberated from CA4-beta Gals by beta-galactosidase, an enzyme more strongly expressed in ovarian cancer cells than normal cells. CA4-beta Gal-2, which has a self-immolative benzyl linker between CA4 and the beta-galactose moiety, was more cytotoxic to ovarian cancer cell lines than CA4-beta Gal-1 without a linker. Therefore, CA4-beta Gal-2 can serve as a platform for the design and manufacture of prodrugs for ovarian cancer PMT.

  DOI：

  10.1021/acsmedchemlett.6b00427

文献信息

• Loiseau; Bonnafous; Caujolle, Il Farmaco, 1990, vol. 45, # 9, p. 953 - 963
  作者：Loiseau、Bonnafous、Caujolle、Payard、Loiseau、Bories、Gayral

  DOI：——

  日期：——
• Bernthsen, Justus Liebigs Annalen der Chemie, 1878, vol. 192, p. 5,19
  作者：Bernthsen

  DOI：——

  日期：——
• LOISEAU, PHILIPPE RAYMOND;BONNAFOUS, MONIQUE;CAUJOLLE, RAYMOND;PAYARD, MA+, FARMACO, 45,(1990) N, C. 953-963
  作者：LOISEAU, PHILIPPE RAYMOND、BONNAFOUS, MONIQUE、CAUJOLLE, RAYMOND、PAYARD, MA+

  DOI：——

  日期：——
• Combretastatin A4-β-Galactosyl Conjugates for Ovarian Cancer Prodrug Monotherapy
  作者：Tomohiro Doura、Kazuaki Takahashi、Yasumitsu Ogra、Noriyuki Suzuki

  DOI：10.1021/acsmedchemlett.6b00427

  日期：2017.2.9

  Chemotherapy for ovarian cancer often causes severe side effects. As candidates for combretastatin A4 (CA4) prodrug for ovarian cancer prodrug monotherapy (PMT), we designed and synthesized two beta-galactose-conjugated CA4s (CA4-beta Gals), CA4-beta Gal-1 and CA4-beta Gal-2. CA4 was liberated from CA4-beta Gals by beta-galactosidase, an enzyme more strongly expressed in ovarian cancer cells than normal cells. CA4-beta Gal-2, which has a self-immolative benzyl linker between CA4 and the beta-galactose moiety, was more cytotoxic to ovarian cancer cell lines than CA4-beta Gal-1 without a linker. Therefore, CA4-beta Gal-2 can serve as a platform for the design and manufacture of prodrugs for ovarian cancer PMT.
• Novel inhibitors of influenza sialidases related to zanamivir. Heterocyclic replacements of the glycerol sidechain
  作者：Paul W. Smith、Andrew R. Whittington、Steven L. Sollis、Peter D. Howes、Neil R. Taylor

  DOI：10.1016/s0960-894x(97)00399-5

  日期：1997.9

  A series of substituted 4-amino-4H-pyran-2-carboxylic acid 6-triazoles and oxadiazoles are described. The compounds are inhibitors of influenza virus sialidases which: in general, show a similar pattern of activity and selectivity to recently reported 4H-pyran-2-carboxylic acid 6-carboxamides. (C) 1997 Elsevier Science Ltd.